Nektar Therapeutics
NKTR.O- Latest Trade
- trading higher3.8USD
- Change
- 0
- % Change
0.00%
- Day Range
- 3.74 - 3.93
- 52-Week Range
- 3.02 - 19.37
As of Jul 1 2022. Values delayed up to 15 minutes
- Previous Close
- 3.80
- Open
- 3.93
- Volume
- 2,748,589.00
- 3 Month Average Trading Volume
- 83.08
- Shares Out (Mil)
- 186.27
- Market Cap
- 737.65
- Forward P/E
- -1.80
- Dividend Yield
- -99,999.99
Key Statistics
3 mean rating - 13 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 7.16
- Price To Book (Quarterly)
- 1.21
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -43.63
- Return On Equity (TTM)
- -39.61
2021 (millions USD)
About Nektar Therapeutics
Company Information
Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Address
455 Mission Bay Blvd SSAN FRANCISCO, CA
94158-2158
United States
Industry
Business Services
Executive Leadership
- Robert B. Chess
- Independent Chairman of the Board
- Howard W. Robin
- President, Chief Executive Officer, Director
- Gilbert M Labrucherie
- Chief Financial Officer, Chief Operating Officer, Senior Vice President
- Jillian B. Thomsen
- Senior Vice President - Finance, Chief Accounting Officer
- Mark A. Wilson
- Senior Vice President, General Counsel
- Robert Bacci
- Senior Vice President of Human Resources and Facilities
- Kevin Brodbeck
- Senior Vice President - Manufacturing
- Brian L. Kotzin
- Senior Vice President, Chief Medical Officer
- Jennifer Ruddock
- Senior Vice President - Strategy and Corporate Affairs
- Mary Tagliaferri
- Senior Vice President, Executive Clinical Fellow
- Jonathan Zalevsky
- Chief Research and Development Officer
- Roy A. Whitfield
- Lead Independent Director
- Jeff Robert Ajer
- Independent Director
- Diana Brainard
- Independent Director
- Myriam J. Curet
- Independent Director
- Karin Eastham
- Independent Director
- R. Scott Greer
- Independent Director
Latest News
- BusinessNektar to cut over 500 jobs following cancer drug failure
Nektar Therapeutics said on Monday it would lay off about 70% of its workforce, or more than 500 employees, after stopping the development of its key cancer drug earlier in the month.
- MarketsTesla, Apple, ExxonMobil
U.S. stock index futures rose on Monday as investors clung to hopes of Russia-Ukraine peace talks, with bank stocks higher ahead of a Federal Reserve policy meeting this week where it is widely expected to raise interest rates.
- MarketsNike, Ebix, Cano Health
The tech-heavy Nasdaq surged 3% on Wednesday, leading a rally on Wall Street as sharp losses this week from worries over the fallout of the Ukraine crisis saw investors scoop up beaten-down stocks, with sentiment lifted by a pullback in oil prices.
- MarketsAmerican Airlines, Oatly Group, Abbvie
Wall Street's main indexes rallied on Wednesday as investors piled into banking and technology sectors that have suffered sharp losses this week on concerns about the fallout from the Ukraine crisis, with sentiment lifted by a fall in oil prices.
- MarketsYEXT Inc, Stitch Fix, Match Group
Wall Street's main indexes were set to bounce back on Wednesday after four straight sessions of losses as oil prices eased and investors snapped up stocks hammered by concerns over Western sanctions on Russia following its invasion of Ukraine.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,795.50 | 0.48%Negative |
| Copper | 682.80 | 1.64%Negative |
| Brent Crude Oil | 108.20 | 0.76%Negative |
| CBOT Soybeans | 1,654.00 | 1.25%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,785.38 | 0.88%Negative |
| Euro STOXX 50 | 3,454.86 | -- |
| FTSE 100 | 7,169.28 | 1.96%Negative |
| Nikkei 225 | 25,923.73 | 1.78%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes